Immune checkpoint inhibitors are a type of immunotherapy that uses the immune system’s natural ability to fight cancer. Immunotherapy is an active area of research for different MBC subtypes. Keytruda® and Jemperli® are currently approved immune checkpoint inhibitors for metastatic breast cancer. Examples of immune checkpoint inhibitors under investigation for MBC include nivolumab, avelumab, and atezolizumab.
Click the links below for an introduction to immune checkpoint inhibitors and information about immune checkpoint inhibitors for MBC.
Introduction to Immune Checkpoint Inhibitors
- NEW MedPage Today (Abstract): Summary of Immune Checkpoint Inhibitors in Clinical Trials
- National Cancer Institute (Video): Immune Checkpoint Inhibitors
- Genentech (Video): PD-L1/PD-1 Pathway
- American Cancer Society: Immune Checkpoint Inhibitors for Breast Cancer
Immune Checkpoint Inhibitors Approved for MBC
- Breastcancer.org: Immunotherapy
- Breastcancer.org: Pembrolizumab (Keytruda®)
- Breastcancer.org: Dostarlimab (Jemperli®)
Immune Checkpoint Inhibitors in MBC Clinical Trials
- Journal Article:Immune Checkpoint Inhibitors Under Development in Breast Cancer
Clinical Trials That Include Immune Checkpoint Inhibitors
- Metastatic Trial Search: MBC Trials That Include PD-1/PD-L1 Immune Checkpoint Inhibitors
- Metastatic Trial Search: MBC Trials That Include CTLA-4 Immune Checkpoint Inhibitors
- Solid Tumor Trials: Trials That May Include Immune Checkpoint Inhibitors
Last Modified on September 26, 2023